Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 337 entries
Sorted by: Best Match Show Resources per page
Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones.

Biopharmaceutics & drug disposition

Lehr M, Fabian J, Hanekamp W.
PMID: 25765813
Biopharm Drug Dispos. 2015 Sep;36(6):398-404. doi: 10.1002/bdd.1946. Epub 2015 Apr 14.

Recently, it was found that the carbonyl group of 1-[3-(4-phenoxyphenoxy)-2-oxopropyl]indole-5-carboxylic acid (5), an inhibitor of the pro-inflammatory enzyme cytosolic phospholipase A

Cite
Lehr M, Fabian J, Hanekamp W. Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones. Biopharm Drug Dispos. 2015;36(6):398-404doi: 10.1002/bdd.1946.
Lehr, M., Fabian, J., & Hanekamp, W. (2015). Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones. Biopharmaceutics & drug disposition, 36(6), 398-404. https://doi.org/10.1002/bdd.1946
Lehr, Matthias, et al. "Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones." Biopharmaceutics & drug disposition vol. 36,6 (2015): 398-404. doi: https://doi.org/10.1002/bdd.1946
Lehr M, Fabian J, Hanekamp W. Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones. Biopharm Drug Dispos. 2015 Sep;36(6):398-404. doi: 10.1002/bdd.1946. Epub 2015 Apr 14. PMID: 25765813.
Copy Download .nbib Format: NLM
Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.

Scientific reports

Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H.
PMID: 29116110
Sci Rep. 2017 Nov 07;7(1):15260. doi: 10.1038/s41598-017-14858-z.

A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.

Cite
Hu C, Yu M, Ren Y, et al. Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep. 2017;7(1):15260doi: 10.1038/s41598-017-14858-z.
Hu, C., Yu, M., Ren, Y., Li, K., Maggio, D. M., Mei, C., Ye, L., Wei, J., Jin, J., Zhuang, Z., & Tong, H. (2017). Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Scientific reports, 7(1), 15260. https://doi.org/10.1038/s41598-017-14858-z
Hu, Chao, et al. "Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation." Scientific reports vol. 7,1 (2017): 15260. doi: https://doi.org/10.1038/s41598-017-14858-z
Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H. Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep. 2017 Nov 07;7(1):15260. doi: 10.1038/s41598-017-14858-z. PMID: 29116110; PMCID: PMC5677121.
Copy Download .nbib Format: NLM
Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.

Journal of clinical imaging science

Rota E, Vallisa D, Morelli N, Scagnelli P.
PMID: 27014503
J Clin Imaging Sci. 2016 Feb 26;6:7. doi: 10.4103/2156-7514.177553. eCollection 2016.

Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological syndrome mostly related to hypertension, eclampsia, renal failure, or to chemotherapy and/or immunosuppressive drugs. Although the PRES pathophysiology is multifactorial, hypertension and endothelial dysfunction are hypothesized to be the...

Cite
Rota E, Vallisa D, Morelli N, et al. Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. J Clin Imaging Sci. 2016;6:7doi: 10.4103/2156-7514.177553.
Rota, E., Vallisa, D., Morelli, N., & Scagnelli, P. (2016). Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. Journal of clinical imaging science, 67. https://doi.org/10.4103/2156-7514.177553
Rota, Eugenia, et al. "Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy." Journal of clinical imaging science vol. 6 (2016): 7. doi: https://doi.org/10.4103/2156-7514.177553
Rota E, Vallisa D, Morelli N, Scagnelli P. Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy. J Clin Imaging Sci. 2016 Feb 26;6:7. doi: 10.4103/2156-7514.177553. eCollection 2016. PMID: 27014503; PMCID: PMC4785783.
Copy Download .nbib Format: NLM
Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report.

Oncology letters

Ma H, Liu T.
PMID: 27313707
Oncol Lett. 2016 Jun;11(6):3858-3862. doi: 10.3892/ol.2016.4452. Epub 2016 Apr 18.

Donor cell leukemia (DCL) is a rare complication of hematopoietic stem cell transplantation (HSCT) which occurs in ~5% of all leukemic relapses. In the English literature, >60 cases of DCL have been reported, however, only two cases of DCL...

Cite
Ma H, Liu T. Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report. Oncol Lett. 2016;11(6):3858-3862doi: 10.3892/ol.2016.4452.
Ma, H., & Liu, T. (2016). Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report. Oncology letters, 11(6), 3858-3862. https://doi.org/10.3892/ol.2016.4452
Ma, Hongbing, and Liu, Ting. "Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report." Oncology letters vol. 11,6 (2016): 3858-3862. doi: https://doi.org/10.3892/ol.2016.4452
Ma H, Liu T. Development of donor cell leukemia following peripheral blood stem cell transplantation for severe aplastic anemia: A case report. Oncol Lett. 2016 Jun;11(6):3858-3862. doi: 10.3892/ol.2016.4452. Epub 2016 Apr 18. PMID: 27313707; PMCID: PMC4888078.
Copy Download .nbib Format: NLM
Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases.

Leukemia & lymphoma

Fenaux P, Vandenbossche-Simon L, Pollet JP, Nelken B, Zandecki M, Bauters F.
PMID: 27457044
Leuk Lymphoma. 1990;2(6):399-405. doi: 10.3109/10428199009069293.

We report 11 children (aged less than 20 years) with acute promyelocytic leukemia (APL), who represented 14% of our total number of patients with APL. There were 8 girls and 3 boys and the median age was 13.5 (range...

Cite
Fenaux P, Vandenbossche-Simon L, Pollet JP, et al. Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases. Leuk Lymphoma. 1990;2(6):399-405doi: 10.3109/10428199009069293.
Fenaux, P., Vandenbossche-Simon, L., Pollet, J. P., Nelken, B., Zandecki, M., & Bauters, F. (1990). Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases. Leukemia & lymphoma, 2(6), 399-405. https://doi.org/10.3109/10428199009069293
Fenaux, P, et al. "Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases." Leukemia & lymphoma vol. 2,6 (1990): 399-405. doi: https://doi.org/10.3109/10428199009069293
Fenaux P, Vandenbossche-Simon L, Pollet JP, Nelken B, Zandecki M, Bauters F. Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases. Leuk Lymphoma. 1990;2(6):399-405. doi: 10.3109/10428199009069293. PMID: 27457044.
Copy Download .nbib Format: NLM
A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.

Frontiers in genetics

Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti TA, Riggs WK.
PMID: 24273552
Front Genet. 2013 Nov 11;4:231. doi: 10.3389/fgene.2013.00231. eCollection 2013.

Anthracyclines are very effective chemotherapeutic agents; however, their use is hampered by the treatment-induced cardiotoxicity. Genetic variants that help define patient's sensitivity to anthracyclines will greatly improve the design of optimal chemotherapeutic regimens. However, identification of such variants is...

Cite
Lubieniecka JM, Graham J, Heffner D, et al. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front Genet. 2013;4:231doi: 10.3389/fgene.2013.00231.
Lubieniecka, J. M., Graham, J., Heffner, D., Mottus, R., Reid, R., Hogge, D., Grigliatti, T. A., & Riggs, W. K. (2013). A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Frontiers in genetics, 4231. https://doi.org/10.3389/fgene.2013.00231
Lubieniecka, Joanna M, et al. "A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor." Frontiers in genetics vol. 4 (2013): 231. doi: https://doi.org/10.3389/fgene.2013.00231
Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti TA, Riggs WK. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Front Genet. 2013 Nov 11;4:231. doi: 10.3389/fgene.2013.00231. eCollection 2013. PMID: 24273552; PMCID: PMC3822292.
Copy Download .nbib Format: NLM
Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan.

BMJ open

Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA.
PMID: 24259388
BMJ Open. 2013 Nov 20;3(11):e003663. doi: 10.1136/bmjopen-2013-003663.

OBJECTIVES: To identify anthracycline-induced acute (within 1 month) and early-onset chronic progressive (within 1 year) cardiotoxicity in children younger than 16 years of age with childhood malignancies at a tertiary care centre of Pakistan.DESIGN: Prospective cohort study.SETTING: Aga Khan...

Cite
Shaikh AS, Saleem AF, Mohsin SS, et al. Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open. 2013;3(11):e003663doi: 10.1136/bmjopen-2013-003663.
Shaikh, A. S., Saleem, A. F., Mohsin, S. S., Alam, M. M., & Ahmed, M. A. (2013). Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ open, 3(11), e003663. https://doi.org/10.1136/bmjopen-2013-003663
Shaikh, Abdul Sattar, et al. "Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan." BMJ open vol. 3,11 (2013): e003663. doi: https://doi.org/10.1136/bmjopen-2013-003663
Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA. Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open. 2013 Nov 20;3(11):e003663. doi: 10.1136/bmjopen-2013-003663. PMID: 24259388; PMCID: PMC3840341.
Copy Download .nbib Format: NLM
Advanced and controlled drug delivery systems in clinical disease management.

Pharmacy world & science : PWS

Brouwers JR.
PMID: 8933575
Pharm World Sci. 1996 Oct;18(5):153-62. doi: 10.1007/BF00820726.

Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted. Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis...

Cite
Brouwers JR. Advanced and controlled drug delivery systems in clinical disease management. Pharm World Sci. 1996;18(5):153-62doi: 10.1007/BF00820726.
Brouwers, J. R. (1996). Advanced and controlled drug delivery systems in clinical disease management. Pharmacy world & science : PWS, 18(5), 153-62. https://doi.org/10.1007/BF00820726
Brouwers, J R. "Advanced and controlled drug delivery systems in clinical disease management." Pharmacy world & science : PWS vol. 18,5 (1996): 153-62. doi: https://doi.org/10.1007/BF00820726
Brouwers JR. Advanced and controlled drug delivery systems in clinical disease management. Pharm World Sci. 1996 Oct;18(5):153-62. doi: 10.1007/BF00820726. PMID: 8933575.
Copy Download .nbib Format: NLM
Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs.

Drug metabolism and pharmacokinetics

Wada A, Sakaeda T, Takara K, Hirai M, Kimura T, Ohmoto N, Zhou J, Nakamura T, Kobayashi H, Okamura N, Yagami T, Okumura K.
PMID: 15618698
Drug Metab Pharmacokinet. 2002;17(5):467-74. doi: 10.2133/dmpk.17.467.

St John's wort (SJW) is Hypericum perforatum L., Hypericaceae, a herbaceous perennial plant native to Europe and Asia, and its various preparations are widely used for the treatment of mild-to-moderately severe depressive disorders. With increasingly prevalent use, the interactions...

Cite
Wada A, Sakaeda T, Takara K, et al. Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet. 2002;17(5):467-74doi: 10.2133/dmpk.17.467.
Wada, A., Sakaeda, T., Takara, K., Hirai, M., Kimura, T., Ohmoto, N., Zhou, J., Nakamura, T., Kobayashi, H., Okamura, N., Yagami, T., & Okumura, K. (2002). Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug metabolism and pharmacokinetics, 17(5), 467-74. https://doi.org/10.2133/dmpk.17.467
Wada, Atsushi, et al. "Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs." Drug metabolism and pharmacokinetics vol. 17,5 (2002): 467-74. doi: https://doi.org/10.2133/dmpk.17.467
Wada A, Sakaeda T, Takara K, Hirai M, Kimura T, Ohmoto N, Zhou J, Nakamura T, Kobayashi H, Okamura N, Yagami T, Okumura K. Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet. 2002;17(5):467-74. doi: 10.2133/dmpk.17.467. PMID: 15618698.
Copy Download .nbib Format: NLM
Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient.

International journal of nephrology and renovascular disease

Turkmen K, Altintepe L, Guney I, Aydogdu I, Koc O, Erkut MA, Tonbul HZ.
PMID: 21694931
Int J Nephrol Renovasc Dis. 2010;3:65-8. doi: 10.2147/ijnrd.s11077. Epub 2010 Jun 04.

Leukemic infiltration of the kidney is usually silent, and the admission of the patients with renal dysfunction or acute kidney injury is uncommon. We present a 34-year old hemodialysis patient with new onset of uncontrolled hypertension, erythropoietin-resistant anemia, thrombocytopenia,...

Cite
Turkmen K, Altintepe L, Guney I, et al. Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. Int J Nephrol Renovasc Dis. 2010;3:65-8doi: 10.2147/ijnrd.s11077.
Turkmen, K., Altintepe, L., Guney, I., Aydogdu, I., Koc, O., Erkut, M. A., & Tonbul, H. Z. (2010). Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. International journal of nephrology and renovascular disease, 365-8. https://doi.org/10.2147/ijnrd.s11077
Turkmen, Kultigin, et al. "Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient." International journal of nephrology and renovascular disease vol. 3 (2010): 65-8. doi: https://doi.org/10.2147/ijnrd.s11077
Turkmen K, Altintepe L, Guney I, Aydogdu I, Koc O, Erkut MA, Tonbul HZ. Uncontrolled hypertension secondary to leukemic cell infiltration of kidneys in a hemodialysis patient. Int J Nephrol Renovasc Dis. 2010;3:65-8. doi: 10.2147/ijnrd.s11077. Epub 2010 Jun 04. PMID: 21694931; PMCID: PMC3108775.
Copy Download .nbib Format: NLM
Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment.

International seminars in surgical oncology : ISSO

Morsi H, Yong KL, Jewell AP.
PMID: 15380050
Int Semin Surg Oncol. 2004 Sep 20;1(1):7. doi: 10.1186/1477-7800-1-7.

BACKGROUND: The control of proliferation, differentiation and survival of normal and malignant cells in the tumour microenvironment is under the control of a wide range of different factors, including cell:cell interactions, cytokines, growth factors and hormonal influences. However, the...

Cite
Morsi H, Yong KL, Jewell AP. Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment. Int Semin Surg Oncol. 2004;1(1):7doi: 10.1186/1477-7800-1-7.
Morsi, H., Yong, K. L., & Jewell, A. P. (2004). Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment. International seminars in surgical oncology : ISSO, 1(1), 7. https://doi.org/10.1186/1477-7800-1-7
Morsi, Hisham, et al. "Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment." International seminars in surgical oncology : ISSO vol. 1,1 (2004): 7. doi: https://doi.org/10.1186/1477-7800-1-7
Morsi H, Yong KL, Jewell AP. Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment. Int Semin Surg Oncol. 2004 Sep 20;1(1):7. doi: 10.1186/1477-7800-1-7. PMID: 15380050; PMCID: PMC522824.
Copy Download .nbib Format: NLM
The application of poly(N-isopropylacrylamide)-co-polystyrene nanofibers as an additive agent to facilitate the cellular uptake of an anticancer drug.

Nanotechnology

Song M, Guo D, Pan C, Jiang H, Chen C, Zhang R, Gu Z, Wang X.
PMID: 21825633
Nanotechnology. 2008 Apr 23;19(16):165102. doi: 10.1088/0957-4484/19/16/165102. Epub 2008 Mar 18.

In this paper, we have fabricated poly(N-isopropylacrylamide)-co-polystyrene (PNIPAM-co-PS) nanofibers by electrospinning and explored the possibility to utilize the PNIPAM-co-PS nanofibers to enhance the permeation and uptake of the anticancer drug daunorubicin in drug-sensitive and drug-resistant leukemia K562 cells. Our...

Cite
Song M, Guo D, Pan C, et al. The application of poly(N-isopropylacrylamide)-co-polystyrene nanofibers as an additive agent to facilitate the cellular uptake of an anticancer drug. Nanotechnology. 2008;19(16):165102doi: 10.1088/0957-4484/19/16/165102.
Song, M., Guo, D., Pan, C., Jiang, H., Chen, C., Zhang, R., Gu, Z., & Wang, X. (2008). The application of poly(N-isopropylacrylamide)-co-polystyrene nanofibers as an additive agent to facilitate the cellular uptake of an anticancer drug. Nanotechnology, 19(16), 165102. https://doi.org/10.1088/0957-4484/19/16/165102
Song, Min, et al. "The application of poly(N-isopropylacrylamide)-co-polystyrene nanofibers as an additive agent to facilitate the cellular uptake of an anticancer drug." Nanotechnology vol. 19,16 (2008): 165102. doi: https://doi.org/10.1088/0957-4484/19/16/165102
Song M, Guo D, Pan C, Jiang H, Chen C, Zhang R, Gu Z, Wang X. The application of poly(N-isopropylacrylamide)-co-polystyrene nanofibers as an additive agent to facilitate the cellular uptake of an anticancer drug. Nanotechnology. 2008 Apr 23;19(16):165102. doi: 10.1088/0957-4484/19/16/165102. Epub 2008 Mar 18. PMID: 21825633.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 337 entries